AVRO News and Press, AVROBIO Inc. From 05/23/23

2023-05-23 06:00:00 ET 3 Tips for Handling High Volatility When Trading Penny Stocks Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inhe...

2023-05-22 07:44:42 ET Avrobio, Inc ( NASDAQ: AVRO ) spiked ~69% in the pre-market trading Monday after the clinical-stage biotech announced an agreement to sell its hematopoietic stem cell (HSC) gene therapy program targeted at cystinosis to Novartis ( NYSE: NVS ). ...

All-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an...

All patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable reduction in leukocyte cystine levels across all patients Received positive regulatory feedback from US and UK agencies AVROBIO, Inc. (Nasdaq: AVRO), a...

2023-05-12 15:00:44 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-05-11 09:49:29 ET AVROBIO press release ( NASDAQ: AVRO ): Q1 GAAP EPS of -$0.57 misses by $0.01 . As of March 31, 2023, AVROBIO had $72.3 million in cash and cash equivalents, as compared to $92.6 million in cash and cash equivalents as of Dec. 31, 2022. For...

On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to ini...

2023-05-01 07:43:30 ET Gene therapy company AVROBIO ( NASDAQ: AVRO ) said on Monday that CFO Erik Ostrowski has been appointed to the additional post of interim CEO, effective today. Ostrowski succeeds founding president and CEO Geoff MacKay. MacKay is leaving the com...

Current CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as int...

2023-03-23 07:56:54 ET AVROBIO press release ( NASDAQ: AVRO ): Q4 GAAP EPS of -$0.57 misses by $0.12 . As of Dec. 31, 2022, AVROBIO had $92.6 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of Dec. 31, 2021. Based on ...